Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Boxer Capital, LLC is a biotechnology investment firm founded in 2005 and based in San Diego, California. The firm focuses on fundamental, research-based investing in specialized and precision medicine companies across both private and public markets. Boxer Capital has built a reputation for identifying transformative medical advancements in precision medicine, leveraging a team that includes experienced scientists and former executives from notable biotech companies.
Since its inception, Boxer Capital has engaged in a disciplined investment approach, emphasizing a multi-disciplinary analysis that incorporates scientific, clinical, commercial, and regulatory factors. The firm has successfully invested in 74 private companies since 2014, achieving 51 liquidity events, including IPOs and acquisitions. This track record highlights Boxer Capital's commitment to innovation and its strategic positioning within the biotechnology sector.
Boxer Capital invests across all stages of the biotechnology ecosystem, including company building, early-stage, late-stage, and crossover investments into public markets. The firm specifically targets biotechnology companies involved in the drug life cycle, focusing on novel drug targets and transformative medical advancements. Their investment strategy employs a disciplined analysis approach that considers scientific, clinical, commercial, and regulatory factors, ensuring a comprehensive evaluation of potential investments.
The firm seeks to identify opportunities that align with its focus on precision medicine, which includes advancements in specialized therapies and innovative drug development. Boxer Capital's investment philosophy is rooted in a deep understanding of the biotechnology landscape, allowing them to respond effectively to changes and trends within the sector.
Boxer Capital has invested in a diverse range of biotechnology companies, with a total of 74 private investments since 2014. The firm has achieved 51 liquidity events, which include IPOs and acquisitions, showcasing its successful investment strategy. Notable portfolio companies include:
These companies exemplify Boxer Capital's commitment to investing in transformative medical advancements and highlight the firm's expertise in the biotechnology sector.
Chris: Founder of Boxer Capital, Chris has extensive experience in biotechnology investments and a strong background in research-based investing.
Aaron: Senior Investment Team Member, Aaron contributes significant expertise in evaluating biotechnology companies and investment opportunities.
Rahul Kakkar, M.D.: Former CEO of Pandion Therapeutics, Rahul brings a wealth of knowledge in drug development and clinical research.
Chuck Baum, M.D., Ph.D.: Former CEO of Mirati Therapeutics, Chuck has a strong background in precision oncology and drug discovery.
Mark McKenna: Former CEO of Prometheus Biosciences, Mark has extensive experience in the biotechnology sector, particularly in autoimmune diseases.
To pitch Boxer Capital, founders should send their pitch deck via email to the general inquiries address. The deck should include comprehensive information about the startup's technology, market opportunity, and team qualifications. A warm introduction is preferred but not mandatory. Founders can expect a response within a few weeks, depending on the volume of inquiries.
In recent months, Boxer Capital has continued to expand its portfolio, focusing on investments in companies that are advancing precision medicine. The firm has successfully led or co-led 14 private investments, demonstrating its active role in the biotechnology sector.
Boxer Capital's commitment to identifying transformative medical advancements remains a key aspect of its strategy, as evidenced by its ongoing engagement with portfolio companies and participation in industry events.
What are Boxer Capital's investment criteria?
Boxer Capital focuses on biotechnology companies involved in the drug life cycle, particularly those targeting novel drug advancements. The firm employs a disciplined analysis approach that considers scientific, clinical, commercial, and regulatory factors.
How can I pitch to Boxer Capital?
Founders can reach out via email to the general inquiries address provided on their website. A well-prepared pitch deck should include details about the company's technology, market potential, and team background.
What makes Boxer Capital different from other investors?
Boxer Capital's unique approach combines a deep understanding of the biotechnology landscape with a team of experienced scientists and executives. This expertise allows them to identify transformative medical advancements effectively.
What is Boxer Capital's geographic focus?
The firm operates across both private and public markets, primarily focusing on biotechnology companies based in the United States, but they may consider international opportunities that align with their investment thesis.
What is the typical check size for Boxer Capital?
While specific check sizes are not disclosed, Boxer Capital invests across all stages of the biotechnology ecosystem, indicating a flexible approach to funding based on the needs of the companies they support.
What kind of post-investment involvement does Boxer Capital have?
Boxer Capital typically engages with portfolio companies through board involvement and operational support, leveraging their team's expertise to help guide companies toward successful outcomes.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.